<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655707</url>
  </required_header>
  <id_info>
    <org_study_id>HHSC/001</org_study_id>
    <nct_id>NCT00655707</nct_id>
  </id_info>
  <brief_title>A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency</brief_title>
  <official_title>A Phase I/II Safety and Tolerability Dose Escalation Study Following the Autologous Infusion of Expanded Adult Haematopoietic Stem Cells to Patients With Liver Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective dose escalation study of the administration of adult human stem cells
      in patients with end stage liver failure. Successive groups of two patients will receive
      ascending doses of autologous adult human stem cells starting at 1x10[9] cells. Following
      expansion in an approved Good Manufacturing Practice (GMP) facility the cells will be infused
      into either the hepatic artery or portal vein of research participants.

      The aim of this trial is to determine the maximum tolerated dose of autologous adult stem
      cells when infused into either the hepatic artery or the portal vein. The maximum dose that
      would be given would be 5x10 to the ten [10].

      To assess improvement in liver function as measured by serological and biochemical analysis
      and determine whether there are any symptomatic improvements as reported by the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective dose escalation study of the administration of expanded autologous
      adult human stem cells in patients with chronic liver insufficiency. Four groups of two
      patients will receive ascending doses of autologous adult human stem cells starting at a dose
      of 1 x 10[8] cells. The cells will be infused into either the hepatic artery or the portal
      vein of research participants. The consultant radiologist will review a duplex Doppler scan
      of the blood supply to the liver to determine the safest route for delivery of the cells.

      The first patients (01 and 02) will receive 1 x 10[8] cells. If no adverse events are
      observed in either patient in the two-week period post stem cell administration, patient
      numbers 03 and 04 will receive 5 x 1[08] cells. This will continue through patients 05 and 06
      receiving cells at 1 x 10[9] and 07 and 08 receiving 5 x 10[9] cells. If any patient in any
      cohort suffers adverse events considered to be treatment-related, the next group of patients
      will receive cells at a concentration one step down from that received by the patient
      suffering the adverse events.

      At the completion of this first stage of the study, if no adverse treatment related events
      are seen, a further group of 10 patients will receive cells at a concentration of 5 x 10[9]
      cells.

      It should be noted that if fewer cells are obtained at the end of the expansion period the
      re-infusion of the cells to the patient should nonetheless continue. This patient will be
      considered inevaluable and the next participant will be allocated their trial number.

      The total period that each patient will be participating in the study is 12 weeks and the
      total duration of this clinical trial is expected to be approximately 12 months.

      All patients will be assessed 4 weeks after coming off study (week 12), whether from
      completion of protocol or early withdrawal for whatever reason. They will also be monitored
      in the clinic for the remainder of their life.

      Patients who are withdrawn due to issues of toxicity will be followed until the adverse event
      is resolved or the outcome is known. Patients will then be followed-up for four weeks after
      resolution and thereafter for life in the clinic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Tolerated the Maximum Dose</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the maximum tolerated dose of autologous adult stem cells when infused into either the hepatic artery or the portal vein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Without Specific Treatment Related Side Effect</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the safety of ascending doses of autologous adult stem cells when introduced into either the hepatic artery or the portal vein and to determine the maximum tolerated dose of stem cells.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Autologous CD34+ cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Cluster Designation 34+(CD34+) cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Expanded CD34+ Haemopoietic cells</intervention_name>
    <description>Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.
Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells</description>
    <arm_group_label>Autologous CD34+ cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged from 20 to 65 years of age

          -  Evidence of chronic liver insufficiency

          -  The presence of abnormal serum albumin and/or bilirubin and/or prothrombin time

          -  Patient is unlikely to receive a liver transplant

          -  Has a World Health Organisation (WHO) performance score of less than 2

          -  Has a life expectancy of at least 3 months

          -  Ability to give written consent

          -  Women of childbearing potential may be included, but must use a reliable and
             appropriate contraceptive method

        Exclusion Criteria:

          -  Patients below the age of 20 or above the age of 65 years

          -  Pregnant or lactating women

          -  Patients with recent recurrent GI bleeding or spontaneous bacterial peritonitis

          -  Patients with evidence of HIV or other life threatening infection

          -  Patients unable to give written consent

          -  Patients with a history of hypersensitivity to Granulocyte-Colony Stimulating Factor
             (F-CSF)

          -  Patients who have been included in any other clinical trial within the previous month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagy Habib, ChM FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>May 7, 2019</results_first_submitted>
  <results_first_submitted_qc>October 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2019</results_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult stem cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The planned dose escalation design did not work due to low participants number. All participants received similar dose of Autologous expanded CD34+ cells .</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Autologous CD34+ cells
Autologous Expanded CD34+ Haemopoietic cells: Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous CD34+ Cells</title>
          <description>Patients enrolled in the study underwent 5 days of treatment with G-CSF to mobilise CD34+ cells, followed by leukapheresis to obtain CD34+ cells.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>20 - 65 years patients</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" lower_limit="42" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Tolerated the Maximum Dose</title>
        <description>To determine the maximum tolerated dose of autologous adult stem cells when infused into either the hepatic artery or the portal vein.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous CD34+ Cells</title>
            <description>Autologous Expanded CD34+ Haemopoietic cells: Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Tolerated the Maximum Dose</title>
          <description>To determine the maximum tolerated dose of autologous adult stem cells when infused into either the hepatic artery or the portal vein.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Without Specific Treatment Related Side Effect</title>
        <description>To assess the safety of ascending doses of autologous adult stem cells when introduced into either the hepatic artery or the portal vein and to determine the maximum tolerated dose of stem cells.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Autologous CD34+ cells
Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Without Specific Treatment Related Side Effect</title>
          <description>To assess the safety of ascending doses of autologous adult stem cells when introduced into either the hepatic artery or the portal vein and to determine the maximum tolerated dose of stem cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous CD34+ Cells</title>
          <description>Autologous Expanded CD34+ Haemopoietic cells: Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Urinary tract infection requiring hospitalisation and antibiotic administration.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea following stem cell injection</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <description>Mild jaundice occurred following the stem cell injection</description>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Mild ascvited developed following stem cell injection</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Mild fever following stem cell injection</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Mild abdominal pain reported following the stem cell injection</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was not a randomised study and although the results were encouraging only a small number of patients were treated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Nagy Habib</name_or_title>
      <organization>ImperialC</organization>
      <phone>+442033138574</phone>
      <email>nagy.habib@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

